Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Box 1023, 3000, Leuven, Flanders, Belgium.
Laboratory for Viral Vector Technology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, Box 1023, 3000, Leuven, Belgium.
Retrovirology. 2019 Apr 2;16(1):8. doi: 10.1186/s12977-019-0472-3.
Persistence of latent, replication-competent provirus is the main impediment towards the cure of HIV infection. One of the critical questions concerning HIV latency is the role of integration site selection in HIV expression. Inhibition of the interaction between HIV integrase and its chromatin tethering cofactor LEDGF/p75 is known to reduce integration and to retarget residual provirus to regions resistant to reactivation. LEDGINs, small molecule inhibitors of the interaction between HIV integrase and LEDGF/p75, provide an interesting tool to study the underlying mechanisms. During early infection, LEDGINs block the interaction with LEDGF/p75 and allosterically inhibit the catalytic activity of IN (i.e. the early effect). When present during virus production, LEDGINs interfere with proper maturation due to enhanced IN oligomerization in the progeny virions (i.e. the late effect).
We studied the effect of LEDGINs present during virus production on the transcriptional state of the residual virus. Infection of cells with viruses produced in the presence of LEDGINs resulted in a residual reservoir that was refractory to activation. Integration of residual provirus was less favored near epigenetic markers associated with active transcription. However, integration near H3K36me3 and active genes, both targeted by LEDGF/p75, was not affected. Also in primary cells, LEDGIN treatment induced a reservoir resistant to activation due to a combined early and late effect.
LEDGINs present a research tool to study the link between integration and transcription, an essential question in retrovirology. LEDGIN treatment during virus production altered integration of residual provirus in a LEDGF/p75-independent manner, resulting in a reservoir that is refractory to activation.
潜伏的、具有复制能力的前病毒的持续存在是治愈 HIV 感染的主要障碍。HIV 潜伏期的一个关键问题是整合位点选择在 HIV 表达中的作用。已知抑制 HIV 整合酶与其染色质固定因子 LEDGF/p75 的相互作用会减少整合,并将残留的前病毒重新靶向到不易被激活的区域。HIV 整合酶与 LEDGF/p75 相互作用的小分子抑制剂 LEDGINs 为研究潜在机制提供了一个有趣的工具。在早期感染过程中,LEDGINs 阻断与 LEDGF/p75 的相互作用,并变构抑制 IN 的催化活性(即早期效应)。当在病毒产生过程中存在时,LEDGINs 由于在后代病毒粒子中增强的 IN 寡聚化而干扰适当的成熟(即晚期效应)。
我们研究了在病毒产生过程中存在的 LEDGINs 对残留病毒转录状态的影响。用在 LEDGIN 存在下产生的病毒感染细胞,导致残留的储库对激活产生抗性。残留前病毒的整合在靠近与活跃转录相关的表观遗传标记处不太有利。然而,靠近 H3K36me3 和活跃基因的整合,这两者都是 LEDGF/p75 的靶点,没有受到影响。在原代细胞中,由于早期和晚期效应的共同作用,LEDGIN 处理也诱导了一个对激活产生抗性的储库。
LEDGINs 为研究整合与转录之间的联系提供了一种研究工具,这是逆转录病毒学中的一个基本问题。在病毒产生过程中使用 LEDGINs 处理以 LEDGF/p75 非依赖性的方式改变了残留前病毒的整合,导致对激活产生抗性的储库。